Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 25;11:737767. doi: 10.3389/fonc.2021.737767

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Kuo, Lu, Chen, Kee, Yen, Hung, Hu, Chen and Wang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Kaplan-Meier survival curves of treatment outcomes including (A) Before Propensity Score (PS)-matched Progression-Free Survival (PFS), (B) After PS-matched PFS, (C) Before PS-matched Time to Progression (TTP), (D) After PS-matched TTP, (E) Before PS-matched Overall Survival (OS), and (F) After PS-matched OS between the Lenvatinib and Sorafenib groups. The Lenvatinib group had superior PFS and TTP, but similar OS to the Sorafenib group, no matter for either before or after PS matching analysis.